Thursday, May 7th | 12:30 PM ET, 6:30 PM CET

What happens when critical information comes too late?

Join Empatica, alongside leading epileptologists, including two authors of the recent Neurology paper “SUDEP Awareness and Effect on Parental Trauma, Grief, and Coping After the Death of a Child”, for an upcoming webinar on how SUDEP (Sudden Unexpected Death in Epilepsy) awareness impacts parental grief and bereavement.

Despite its significance, SUDEP often remains underdiscussed in clinical care. This session brings together clinical expertise, research, and lived experience to explore how gaps in communication affect families, and why earlier, more compassionate conversations are critical.

What we’ll cover:

  • A parent’s lived experience perspective who tragically lost their son to SUDEP
  • Key findings from the recent Neurology study
  • Practical implications for clinical practice
  • The role of training, including AI-based approaches, in supporting better communication with patients
  • Live Q&A with the speakers


Secure your spot
Hear firsthand experiences from families, examine the impact of limited dialogue around SUDEP and learn why timely, empathetic communication is essential to better support both patients and caregivers.

Register to attend

By clicking Register you consent to being contacted by Empatica Inc. about its products and services and you agree to the terms and conditions stated in the privacy policy.

Our special guests

Phillip L. Pearl, M.D. is Director of Epilepsy and Clinical Neurophysiology at Boston Children’s Hospital and William G. Lennox Chair and Professor of Neurology at Harvard Medical School.  He attended Johns Hopkins University and the Peabody Conservatory of Music, and the University of Maryland School of Medicine.  He took his residency at Texas Children’s Hospital/Baylor College of Medicine and fellowship at Boston Children’s Hospital/Harvard Medical School.  He was Division Chief of Neurology at Children’s National and Professor of Neurology, Pediatrics, and Music at the George Washington University School of Medicine until returning to Boston in January 2014.  His major research interest is inherited metabolic epilepsies with specific focus on disorders of GABA metabolism.  Dr. Pearl has published over 275 peer-reviewed manuscripts, over 160 chapters/reviews, and written or edited eight books, one of which is translated into Chinese and one into Japanese.  Dr. Pearl a member of the Music and Health Institute at the Berklee College of Music in Boston, and is Past President of the Professors of Child Neurology and the Child Neurology Society. 

 

Itay Tokatly Latzer, M.D., is a pediatric neurologist and epileptologist specializing in epilepsy and inherited metabolic epilepsies. He is currently an attending physician in Pediatric Neurology and Epilepsy and Director of the Neurostimulation Service at Dana-Dwek Children’s Hospital, Tel Aviv Medical Center, and serves as Senior Lecturer (Assistant Professor) at the Faculty of Medicine, Tel Aviv University, Israel. Dr. Tokatly Latzer completed fellowships in Epilepsy and Metabolic Epilepsies at Boston Children’s Hospital/Harvard Medical School. His research focuses on GABA-related metabolic epilepsies, developmental and epileptic encephalopathies, and SUDEP, with particular emphasis on family experience, counseling, and prevention strategies. He has authored more than 60 peer-reviewed publications and multiple textbook chapters, and is actively involved in international collaborative research, including NIH-funded studies and the ILAE SUDEP Task Force. His work bridges clinical care, translational research, and medical education, with a strong commitment to improving outcomes and communication for children with epilepsy and their families.

 

Our host

 

About Empatica

Empatica is a digital healthcare company headquartered in Boston, MA, and a pioneer in digital biomarker development and continuous patient monitoring driven by AI. For over a decade, Empatica has been makinges medical-grade wearables, software, and digital biomarkers that can accurately monitor human health remotely, continuously, and unobtrusively across a range of conditions. Its technology has helped publish over 12,000 research papers worldwide.

Empatica's FDA-cleared platform is used by thousands of institutional partners for research purposes, in studies examining sleep, stress, epilepsy, migraine, depression, addiction, and other conditions. Its flagship wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and the NASA-funded TRISH. Empatica’s newest device, EmbraceMini, is the world’s smallest actigraphy wearable designed for clinical trials.

Empatica is also a global leader in patient-centric wearable epilepsy monitoring. Its award-winning Embrace watch was the world’s first FDA-cleared smartwatch in neurology, for its ability to detect epileptic seizures. Its successor, EpiMonitor, utilizes the EmbracePlus wearable, and is available in the US and Europe, with both FDA clearance and CE MDR certification.